Showing results (121-130 of 192) with videos related to

Sort By:
Pageof 20
Scientific Reports|February 2, 2017
Pharmacologic ATM but not ATR kinase inhibition abrogates p21-dependent G1 arrest and promotes gastrointestinal syndrome after total body irradiationFrank P Vendetti, Brian J Leibowitz, Jennifer Barnes, et al.
Drug Metabolism and Pharmacokinetics|January 5, 2010
Biotransformation profiling of [(14)C]ixabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS)S Nilgün Cömezoğlu, Van T Ly, Donglu Zhang, et al.
Journal of the National Cancer Institute|January 2, 2017
Disease Subtype-Independent Biomarkers of Breast Cancer Chemoprevention by the Ayurvedic Medicine Phytochemical Withaferin ASuman K Samanta, Anuradha Sehrawat, Su-Hyeong Kim, et al.
Biorxiv : the Preprint Server for Biology|June 5, 2026
Transient ATR inhibition following ionizing radiation enhances immune-mediated antitumor response and survivalJoshua Deppas, Brian F Kiesel, Frank P Vendetti, et al.
Cancer Chemotherapy and Pharmacology|March 18, 2015
Plasma pharmacokinetics of the indenoisoquinoline topoisomerase I inhibitor, NSC 743400, in rats and dogsMiguel Muzzio, Shu-Chieh Hu, Julianne L Holleran, et al.
Clinical and Translational Science|December 5, 2025
Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate CancerNadine Norton, Nicholas B Larson, Gregory D Jenkins, et al.
Medrxiv : the Preprint Server for Health Sciences|May 2, 2025
Phase Ib Study of Enzalutamide with Venetoclax in Patients with Metastatic Castration-Resistant Prostate CancerStuthi Perimbeti, Anmbreen Jamroze, Dharmesh Gopalakrishnan, et al.
Therapeutic Drug Monitoring|November 26, 2009
Multicenter evaluation of a novel nanoparticle immunoassay for 5-fluorouracil on the Olympus AU400 analyzerJan H Beumer, M Boisdron-Celle, William Clarke, et al.
Leukemia & Lymphoma|April 5, 2018
A phase-1 study of dasatinib plus all-trans retinoic acid in acute myeloid leukemiaRobert L Redner, Jan H Beumer, Patricia Kropf, et al.
Neuro-Oncology|March 12, 2015
Phase 2 trial of dasatinib in target-selected patients with recurrent glioblastoma (RTOG 0627)Andrew B Lassman, Stephanie L Pugh, Mark R Gilbert, et al.
Pageof 20